NCT00370097 - FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 30, 2006

Primary Completion Date

April 12, 2007

Study Completion Date

April 12, 2007

Conditions

Asthma

Interventions

DRUG

FLOVENT (fluticasone propionate) HFA

FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask.

DRUG

Placebo HFA

Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask.

Trial Locations (7)

32207

GSK Investigational Site, Jacksonville

61761

GSK Investigational Site, Normal

73112

GSK Investigational Site, Oklahoma City

75230

GSK Investigational Site, Dallas

80112

GSK Investigational Site, Centennial

92647

GSK Investigational Site, Huntington Beach

30309-7520

GSK Investigational Site, Atlanta